Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program Patients With Multiple Sclerosis

Launched by UNIVERSIDAD EUROPEA DE MADRID · Apr 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special exercise program designed to help people with Multiple Sclerosis (MS) improve their core muscle control. The researchers want to see if this program can help with urinary incontinence, sexual dysfunction, balance issues, and even breathing. The goal is to find a way to support patients with MS in managing these problems, which can sometimes happen due to changes in muscle control.

To participate in this study, potential volunteers need to be between the ages of 18 and 70 and have a confirmed diagnosis of MS for at least two years. They should have a certain level of physical ability and be stable on their current medical treatment for at least six months. Participants will engage in this rehabilitation program and will be closely monitored to see how effective it is. This trial aims to provide new insights into helping MS patients live more comfortably and maintain their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Age between 18 and 70 years.
• • Confirmed diagnosis of Multiple Sclerosis based on McDonald criteria, with an evolution time of more than two years (remitting or progressive) (24).
• • Multiple Sclerosis Disability Status Scale (EDSS) score between 2 (minimal disability in one of the functional systems), and 7.5 (inability to take more than a few steps. Limited to wheelchair and transfer support. Ability to move the chair, but not all day if the chair is conventional and lacks a motor) (25, 26).
• • Stable medical treatment for at least six months prior to surgery (26).
• • Absence of cognitive impairment, with ability to understand instructions and score 24 or higher on the Minimental Test (27).
• • Urinary incontinence as a consequence of neurological involvement.
• Exclusion Criteria:
• • - Diagnosis of another neurological disease or musculoskeletal disorder other than MS.
• • Diagnosis of any cardiovascular, respiratory, genitourinary, metabolic or other conditions that may interfere with this study.
• • Having presented urinary incontinence prior to the diagnosis of MS.
• • Have suffered an exacerbation or hospitalisation in the last 3 months before starting the assessment protocol, or during the therapeutic intervention process.
• • Have received a course of intravenous or oral steroids 6 months prior to the start of the assessment protocol and within the intervention period of the study duration.